An interventional study of Insulin 80mU/m2*min in Insulin Stimulated, sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by The University of Texas Health Science Center at San Antonio · Not applicable, Interventional, and Basic science
Among 12 studies in Insulin Resistance by The University of Texas Health Science Center at San Antonio — 3 open to participants now, 3 under way, none of them phase 3. Insulin Resistance · The University of Texas Health Science Center at San Antonio.
Among the 12 studies in Insulin Resistance by The University of Texas Health Science Center at San Antonio, this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 with no phase, and was the 11th registered.
2,969 studies on the registry are indexed under Insulin Resistance; 338 are open to participants now.
Browse Insulin Resistance studies →3 of the 12 studies in Insulin Resistance by The University of Texas Health Science Center at San Antonio are open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
The University of Texas Health Science Center at San Antonio · Sites in United States
By country, each count listing its studies:
Of the 244 Insulin Resistance studies recruiting now, 54 (22%) set no upper age limit and 158 (65%) stop at 75 or younger; 30 take children under 18; 113 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 4 2
First in 2009; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 100 is above the median of 40 across 2,369 interventional studies indexed under Insulin Resistance.
Median enrollment 20 across the 11 interventional studies, 23 across the 1 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
The University of Texas Health Science Center at San Antonio is the lead sponsor of 445 studies on the registry; 89 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 35 (54%) have results posted.
1 of the studies in Insulin Resistance by The University of Texas Health Science Center at San Antonio that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05305287The University of Texas Health Science Center at San AntonioQuantifying Hepatic Mitochondrial Fluxes in Humans | 2027-03-31 |
Among the 12 studies in Insulin Resistance by The University of Texas Health Science Center at San Antonio, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, the investigators will use euglycemic/hyperinsulinemic clamps, longitudinal skeletal muscle biopsies, and single nucleus ribonucleic acid sequencing (RNA-Seq) and assay for transposase-accessible chromatin using sequencing (ATAC- seq) to reveal cell type-specific molecular response quantitative trait loci (rQTLs) acutely regulated by insulin signaling and glucose uptake.
The study investigators seek to find the relationship between basal and insulin stimulated Quantitative trait loci (QTL's) by utilizing vastus lateralis muscle biopsies before and after a euglycemic/hyperinsulinemic clamp. Each participant will have a catheter placed into an antecubital vein for the infusion of all test substances. A second catheter will be inserted retrogradely into a vein on the dorsum of the hand, and the hand will be placed into a thermoregulated box heated to 45 to 50 degrees Celsius. All participants will receive an infusion of [3-3H]glucose. After a 2-h basal tracer equilibration period, participants will receive a prime-continuous insulin infusion at the rate of 80mU/m2*min. During the last 30 min of the basal equilibration period and throughout the insulin infusion, plasma samples will be taken at 5-10 min intervals for the determination of plasma glucose and insulin concentrations and tritiated glucose radioactivity. During the insulin infusion, a variable in-fusion of 20% glucose will be adjusted, based on the negative feedback principle, to maintain the plasma glucose concentration at \~100mg/dL with a coefficient of variation \<5%. Skeletal muscle biopsies will be obtained from the vastus lateralis muscle approximately 1h prior to and at the end of the insulin clamp, and will be snap frozen in liquid nitrogen for nuclei isolation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Fasting blood sugar \< 100 mg/dL 2-hour Oral Glucose Tolerance Test (OGTT) \< 140mg/dL Stable weight over the past 3 months defined as >±5% change in body weight
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
80mU/m2\*min euglycemic/hyperinsulinemic clamp
Other: Insulin 80mU/m2*min
80mU/m2\*min euglycemic-hyperinsulinemic clamp
Cell type specific quantitative trait loci in skeletal muscle
Single nucleus ribonucleic acid sequencing (RNA-Seq) and assay for transposase-accessible chromatin using sequencing (ATAC- seq) will be used to reveal cell type-specific molecular response quantitative trait loci (QTLs) acutely regulated by insulin signaling and glucose uptake
Time frame: Before and after insulin clamp (Baseline to approximately 6 hours)
Plan to share: Yes — Individual Participant data will be deidentified prior to sharing with any external entity at the University of Michigan or the National Institute of Diabetes and Digestive and Kidney Diseases. Any results shared as summary result on ClinicalTrials.gov or in a publication will not have any participant identifiers.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: At the conclusion of the study and after data are analyzed
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jul 2031, 58 months after the start.
Of 714 non-industry interventional studies with no phase under Insulin Resistance, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 58 months is above that.
Counting every sponsor, half of 754 studies reached it within 21 months; a quarter within 9 and three quarters within 40.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Health Science Center at San Antonio →